Precigen posts quarterly profit as PAPZIMEOS sales surge

Precigen

04/08/2026 21:15

Overview
US biopharma firm's Q2 revenue surged on PAPZIMEOS sales, driving quarterly profitability
Company reversed prior-year loss, reporting net income of $20.1 mln for Q2
PAPZIMEOS adoption accelerated, aided by broad US payer coverage and FDA market exclusivity

Outlook
Company expects continued growth in PAPZIMEOS demand during Q3 2026
Precigen expects current cash and PAPZIMEOS revenue to fund operations through cash flow break-even by end-2026
Company plans AdenoVerse portfolio update, including PRGN-2009, by year-end

Result Drivers
PAPZIMEOS SALES - Q2 revenue surge and profitability driven by commercial sales of PAPZIMEOS following FDA approval
BROAD US ADOPTION - Expanding patient hub enrollment and increased site activations supported PAPZIMEOS revenue growth
MARKET EXCLUSIVITY & REIMBURSEMENT - FDA granted PAPZIMEOS seven-year market exclusivity and permanent J-code, aiding access and reducing reimbursement uncertainty

Company press release: ID:nPn8bWfs7a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
 
$20.07 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Precigen, Inc. is $12.50, about 89.1% above its August 3 closing price of $6.61
The stock recently traded at 67 times the next 12-month earnings vs. a P/E of 230 three months ago

Reuters Recommended Reads
Aug 4 - Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand
Aug 3 - Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance
Aug 3 - Latigo, BlossomHill launch US IPOs as biotech listings rebound

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)